Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 1 1

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 6OTHER 3

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6Thoracic 1

Conditions

Prostatic Neoplasms 6Neoplasm Metastasis 1

Interventions

pembrolizumab 164Prednisone 130enzalutamide 127Docetaxel 122Abiraterone Acetate 95Nivolumab 93Gemcitabine 71Sunitinib 67atezolizumab 50abiraterone 50Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48Cisplatin 48radium Ra 223 dichloride 39Sorafenib 39darolutamide 38apalutamide 38Ipilimumab 38Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32cabozantinib 31avelumab 31pazopanib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × ZD4054 × Genitourinary × Clear all
NCT00554229 2016-02-08

ENTHUSE M1

AstraZeneca

Phase 3 Completed
896 enrolled 15 charts
Genitourinary

Prostatic Neoplasms

NCT00314782 2013-03-12

Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC

AstraZeneca

Phase 1 Completed
44 enrolled
Genitourinary

Prostatic Neoplasms

NCT00090363 2013-01-08

ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)

AstraZeneca

Phase 2 Completed
447 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

NCT00055471 2012-10-31

A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

AstraZeneca

Phase 2 Completed
22 enrolled 17 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00617669 2012-09-10

ENTHUSE M1C

AstraZeneca

Phase 3 Completed
1,494 enrolled 14 charts
Genitourinary

Prostatic Neoplasms

NCT00626548 2012-09-03

ENTHUSE M0

AstraZeneca

Phase 3 Terminated
2,577 enrolled 8 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡